Evidence map›Paper›PMID 28232952›Full record

ArticleNPJ breast cancer2017

Identification, validation, and targeting of the mutant p53-PARP-MCM chromatin axis in triple negative breast cancer.

Wei-Gang Qiu, Alla Polotskaia, Gu Xiao, Lia Di, Yuhan Zhao, Wenwei Hu, John Philip, Ronald C Hendrickson, Jill Bargonetti

Open access · goldAbstract read
In one paragraph

Article in NPJ breast cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
2.1field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 47 citations in OpenAlex.

  1. Article
  2. Journal of Cancer · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. MutantCancers · 2022
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

Wei-Gang QiuThe Department of Biological Sciences Hunter College, City University of New York, Hunter College-Weill Cornell Belfer Research Building, 413 East 69th, New York, NY 10065, USA; The Graduate Center PhD Program in Biology, City University of New York, New York, NY 10016, USA; Department of Physiology and Biophysics, Weill Cornell Medical College of Cornell University, New York, NY 10065, USA.
Alla PolotskaiaThe Department of Biological Sciences Hunter College, City University of New York, Hunter College-Weill Cornell Belfer Research Building, 413 East 69th, New York, NY 10065, USA.
Gu XiaoThe Department of Biological Sciences Hunter College, City University of New York, Hunter College-Weill Cornell Belfer Research Building, 413 East 69th, New York, NY 10065, USA.
Lia DiThe Department of Biological Sciences Hunter College, City University of New York, Hunter College-Weill Cornell Belfer Research Building, 413 East 69th, New York, NY 10065, USA.
Yuhan ZhaoRutgers Cancer Institute of New Jersey, New Brunswick, NJ 08903, USA.
Wenwei HuRutgers Cancer Institute of New Jersey, New Brunswick, NJ 08903, USA.
John PhilipProteomics Core Facility, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.
Ronald C HendricksonProteomics Core Facility, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.
Jill BargonettiThe Department of Biological Sciences Hunter College, City University of New York, Hunter College-Weill Cornell Belfer Research Building, 413 East 69th, New York, NY 10065, USA; The Graduate Center PhD Programs in Biology and Biochemistry, City University of New York, New York, NY 10016, USA; Department of Cell and Developmental Biology, Weill Cornell Medical College of Cornell University, New York, NY 10065, USA.
City University of New York · USHunter College · USMemorial Sloan Kettering Cancer Center · USRutgers, The State University of New Jersey · USThe Graduate Center, CUNY · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
Basic and Translational Research Center for Reducing Health DisparitiesG12MD007599 · NIMHD · HUNTER COLLEGE · PI ANGULO, JESUS A · 2012 to 2017
$14.6M
LTQ-ORBITRAP VELOS Tandem Mass SpectrometerS10OD010598 · OD · SLOAN-KETTERING INST CAN RESEARCH · PI HENDRICKSON, RONALD CHARLES · 2012 to 2012
$460k
NCI NIH HHS P30 CA008748NIH HHS S10 OD010598NIMHD NIH HHS G12 MD007599
6 · The paper itself

Abstract

Over 80% of triple negative breast cancers express mutant p53. Mutant p53 often gains oncogenic function suggesting that triple negative breast cancers may be driven by p53 protein type. To determine the chromatin targets of this gain-of-function mutant p53 we used inducible knockdown of endogenous gain-of-function mtp53 in MDA-MB-468 cells in conjunction with stable isotope labeling with amino acids in cell culture and subcellular fractionation. We sequenced over 70,000 total peptides for each corresponding reciprocal data set and were able to identify 3010 unique cytoplasmic fraction proteins and 3403 unique chromatin fraction proteins. The present proteomics experiment corroborated our previous experiment-based results that poly ADP-ribose polymerase has a positive association with mutant p53 on the chromatin. Here, for the first time we report that the heterohexomeric minichromosome maintenance complex that participates in DNA replication initiation ranked as a high mutant p53-chromatin associated pathway. Enrichment analysis identified the minichromosome maintenance members 2-7. To validate this mutant p53- poly ADP-ribose polymerase-minichromosome maintenance functional axis, we experimentally depleted R273H mutant p53 and found a large reduction of the amount of minichromosome maintenance complex proteins on the chromatin. Furthermore a mutant p53-minichromosome maintenance 2 direct interaction was detected. Overexpressed mutant p53, but not wild type p53, showed a protein-protein interaction with minichromosome maintenance 2 and minichromosome maintenance 4. To target the mutant p53- poly ADP-ribose polymerase-minichromosome maintenance axis we treated cells with the poly ADP-ribose polymerase inhibitor talazoparib and the alkylating agent temozolomide and detected synergistic activation of apoptosis only in the presence of mutant p53. Furthermore when minichromosome maintenance 2-7 activity was inhibited the synergistic activation of apoptosis was blocked. This mutant p53- poly ADP-ribose polymerase -minichromosome maintenance axis may be useful for theranostics.

Identifiers

PMID28232952
PMCPMC5319483
OpenAlexW2579756453

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.